Medium impact
Beleodaq® (belinostat)
Humana·Effective Jan 1, 2026
Humana Medicaid Ohio implemented a new prior authorization policy for Beleodaq (belinostat) effective January 1, 2026. The policy requires prior authorization for belinostat treatment in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), with specific approval criteria, two key exclusions (disease progression on Beleodaq or concurrent use of other HDAC inhibitors), and 6-month initial and renewal approval periods.